[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Benefitted from Top-Line Growth From Its Immunosuppressive Drugs",
    "summary": "Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the same can be downloaded here. Global markets were in solidly positive territory for the third straight quarter of 2024 despite geopolitical volatility. Polaris Global Equity Composite (net of fees) returned 6.86% in the quarter, compared to 6.46% […]",
    "url": "https://finnhub.io/api/news?id=9fa95da3b32a8c11a9f4521ba9c59d36fd17f493ea7701ce92d2a734f968eeb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734961709,
      "headline": "AbbVie (ABBV) Benefitted from Top-Line Growth From Its Immunosuppressive Drugs",
      "id": 132120561,
      "image": "https://media.zenfs.com/en/insidermonkey.com/78d74142cf57e6508d3965f20baf778a",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the same can be downloaded here. Global markets were in solidly positive territory for the third straight quarter of 2024 despite geopolitical volatility. Polaris Global Equity Composite (net of fees) returned 6.86% in the quarter, compared to 6.46% […]",
      "url": "https://finnhub.io/api/news?id=9fa95da3b32a8c11a9f4521ba9c59d36fd17f493ea7701ce92d2a734f968eeb4"
    }
  },
  {
    "ts": null,
    "headline": "Is AbbVie Stock a Buy?",
    "summary": "With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to offer to investors.  AbbVie is notable among the major pharma businesses for its smooth execution of its carefully planned pipeline strategy.  In the third quarter, revenue from Rinvoq and Skyrizi was more than $4.8 billion.​​ By 2027, these medicines are expected to bring in a total of more than $27 billion in sales annually across a range of different indications in rheumatology, dermatology, psoriatic diseases, and inflammatory bowel diseases.",
    "url": "https://finnhub.io/api/news?id=b4dc545cbdcd0f9ee08033af888b62329d01e3a43ad374aa8b777fdf9c707b60",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734960600,
      "headline": "Is AbbVie Stock a Buy?",
      "id": 132120562,
      "image": "https://g.foolcdn.com/editorial/images/801761/one-investor-explains-something-to-another-at-a-cafe.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to offer to investors.  AbbVie is notable among the major pharma businesses for its smooth execution of its carefully planned pipeline strategy.  In the third quarter, revenue from Rinvoq and Skyrizi was more than $4.8 billion.​​ By 2027, these medicines are expected to bring in a total of more than $27 billion in sales annually across a range of different indications in rheumatology, dermatology, psoriatic diseases, and inflammatory bowel diseases.",
      "url": "https://finnhub.io/api/news?id=b4dc545cbdcd0f9ee08033af888b62329d01e3a43ad374aa8b777fdf9c707b60"
    }
  },
  {
    "ts": null,
    "headline": "2 Excellent Dividend Stocks to Buy on the Dip",
    "summary": "AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common.  Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.  The company's $8.7 billion buyout of Cerevel Therapeutics now looks like a waste of money after the leading asset it got from that transaction, emraclidine, failed a pair of phase 2 studies.",
    "url": "https://finnhub.io/api/news?id=dd89758c20e726a1dcb8a744f07157cad74c75fb20707e21f3733b108b54b176",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734946320,
      "headline": "2 Excellent Dividend Stocks to Buy on the Dip",
      "id": 132117199,
      "image": "https://g.foolcdn.com/editorial/images/801657/pharmacist-talking-to-patient.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common.  Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.  The company's $8.7 billion buyout of Cerevel Therapeutics now looks like a waste of money after the leading asset it got from that transaction, emraclidine, failed a pair of phase 2 studies.",
      "url": "https://finnhub.io/api/news?id=dd89758c20e726a1dcb8a744f07157cad74c75fb20707e21f3733b108b54b176"
    }
  }
]